Syros Pharmaceuticals Inc (NASDAQ: SYRS) released initial data from its ongoing SELECT-AML-1 Phase 2 trial of tamibarotene in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.